Xilio Therapeutics Inc. (XLO)
XLO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1840233/000119312526118550/0001193125-26-118550-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | XLO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001840233 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $43.8M |
| Net income | -$35.0M |
| Operating income | -$42.0M |
| Net margin | -80.1% |
| Operating margin | -95.9% |
| Revenue growth | +589.9% |
| Cash | $137.5M |
| Total assets | $154.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $122.2M cash; operating cash flow -$14.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 7,063,982 (2026-11-06); 52,500,328 a year earlier; 27,542,000 three years earlier. 1y figure adjusted for split (1-for-14 overall); 3y figure adjusted for split (1-for-14 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-14 on 2026-03-16 | Source 2026-03-16 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 1 at the market | Latest 2026-02-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $44K, sold $6K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $10.0M | -$5.9M | -$13.8M | $122.2M | No debt tags | $55.0M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $18.7M | -$6.4M | -$18.8M | $136.0M | No debt tags | $64.1M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $12.6M | -$9.5M | -$22.3M | $150.3M | No debt tags | $53.5M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $13.7M | $10.4M | -$2.0M | $137.5M | No debt tags | $43.8M | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $19.1M | -$16.3M | -$17.5M | $103.8M | No debt tags | $31.8M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $8.1M | -$15.8M | -$14.5M | $121.6M | No debt tags | $15.0M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $2.9M | -$13.3M | $29.0M | $89.1M | No debt tags | $9.3M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $1.7M | -$13.1M | -$14.2M | $55.3M | No debt tags | $6.3M | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-05-12 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 363 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.3% |
| 1 month | -12.4% |
| 3 months | -10.4% |
| Year to date | -9.9% |
| 1 year | -17.8% |
| From 52-week high | -28.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AZR | Azora Therapeutics Inc. | $3.81 | -6.85% | $54.4M |
| INCR | Intercure Ltd. | $3.63 | -4.22% | $54.5M |
| CING | Cingulate Inc. | $3.75 | -12.79% | $54.5M |
| HRTX | Heron Therapeutics Inc. | $0.2843 | -8.44% | $54.1M |
| VRCA | Verrica Pharmaceuticals Inc. | $3.20 | -10.11% | $55.0M |
| SPRO | Spero Therapeutics Inc. | $0.9464 | -5.35% | $55.1M |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $2.88 | -4.32% | $56.0M |
| CLNN | Clene Inc. | $3.66 | -6.63% | $52.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier